We came across a bullish thesis on Genmab A/S (GMAB) on Substack by Oliver | MMMT Wealth. In this article, we will summarize ...

Genmab (GMAB) announced updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan, an investigational folate ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Genmab (GMAB – Research Report), with a price target ...

Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...

New data from the Phase II RAINFOL-01 study shows rinatabart sesutecan (Rina-S), an investigative antibody-drug conjugate, ...

Genmab has stopped clinical development of a blood cancer treatment after Johnson & Johnson decided it won't exercise its option to license it.

Genmab shares fell on Monday after the company said it would end the development of blood-cancer treatment HexaBody-CD38 because Johnson & Johnson won't exercise its option to license it.

Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their ...

Equities research analysts at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Genmab A/S ...

Genmab A/S (NASDAQ:GMAB – Free Report) had its price target decreased by Truist Financial from $50.00 to $45.00 in a report ...

Genmab (GMAB) announced that Johnson & Johnson (JNJ) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38. “While the ...